(AOF) – The Boiron laboratory announces a net profit, group share, down 19.8% in 2023 to 35.82 million euros, for a turnover down 7.7% to 493.24 million euros. The homeopathy specialist cites a drop in volumes “mainly on sales of Covid tests”, and a negative exchange rate effect. It will propose the distribution of a dividend of 1.35 euros per share to be paid on June 5. The group confirmed at the end of December 2023 its plan to delist following the Simplified Public Purchase Offer (OPAS), the timetable of which will be determined by the AMF.
Over the year 2024, the evolution of the group’s sales and profitability will depend “on the level of seasonal pathologies in the different countries, the launch of new products and the evolution of the global geopolitical situation”, announces Boiron.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
